서브메뉴
검색
Advances in Keratin 17 as a Cancer Biomarker: A Systematic Review
Advances in Keratin 17 as a Cancer Biomarker: A Systematic Review
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20250211151054
- ISBN
- 9798382321417
- DDC
- 610
- 저자명
- Tseng, Robert.
- 서명/저자
- Advances in Keratin 17 as a Cancer Biomarker: A Systematic Review
- 발행사항
- [Sl] : Yale University, 2024
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2024
- 형태사항
- 87 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 85-11, Section: B.
- 주기사항
- Advisor: Escobar-Hoyos, Luisa F.;Shroyer, Kenneth R.
- 학위논문주기
- Thesis (M.D.)--Yale University, 2024.
- 초록/해제
- 요약Background: In an era where tumor heterogeneity leads to widely variable cancer treatment outcomes, there is an unmet need for biomarkers that can characterize tumor subtypes, inform prognosis, and guide clinical decision-making for therapy. As an oncofetal monofilament that is only expressed in embryonic and cancer tissue, keratin 17 (K17) has been demonstrated as an effective biomarker in a wide variety of cancer types, detection methods, and clinical purposes. In order to guide and inform future investigations on K17, we performed a systematic review of clinical studies assessing the effectiveness of K17 as a cancer biomarker.Methods: We performed a literature search of relevant articles reporting K17 as a cancer biomarker prior to December 16th, 2023. After manual review, we assigned articles to diagnostic, prognostic, and predictive study categories. We extracted relevant diagnostic and prognostic statistics, experimental methodologies, and co-examined biomarkers. Additionally, we performed bias analysis utilizing data reported from prognostic studies. Finally, using RNA-seq samples of tumor and normal tissue specimens from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) portal, we perform our own diagnostic analysis across 21 tumor/normal tissue pairs, as well as Kaplan-Meier analysis across 32 cancer types.Results: Of the 453 studies identified in our literature search, we obtained 40 diagnostic, 50 prognostic, and 5 predictive studies. Altogether, we summarized the methodologies of 37 diagnostic studies and ROC (Receiver Operating Curve) analyses provided by 15 articles. Our review suggests that K17 is a highly applicable diagnostic biomarker, characterizable by multiple assay types, to distinguish either malignant from normal pathology, or two different malignant pathologies. For prognostic studies, we extracted Cox proportional hazards models provided by 36 studies, a majority of which suggest that K17 is a negatively prognostic biomarker in a wide range of cancer types, including oropharyngeal, esophageal, gastric, pancreatic, gallbladder, ovarian, and endometrial cancers. Finally, based on our review, K17 is predictive of inferior response to therapy in 4 out of 5 predictive studies.Conclusion: K17 is a widely applicable cancer biomarker that has been shown to be effective in diagnostic settings, and increasingly in patient specimens obtained non-invasively. As both an IHC and RNA-based biomarker, K17 is widely associated with negative prognosis. New predictive studies are beginning to correlate K17 to inferior chemotherapeutic and immunotherapeutic treatment response.
- 일반주제명
- Medicine
- 일반주제명
- Molecular biology
- 일반주제명
- Oncology
- 키워드
- Cancer treatment
- 키워드
- Keratin 17
- 키워드
- Biomarkers
- 기타저자
- Yale University Yale School of Medicine
- 기본자료저록
- Dissertations Abstracts International. 85-11B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008250123s2024 us c eng d■001000017160645
■00520250211151054
■006m o d
■007cr#unu||||||||
■020 ▼a9798382321417
■035 ▼a(MiAaPQ)AAI31141983
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a610
■1001 ▼aTseng, Robert.
■24510▼aAdvances in Keratin 17 as a Cancer Biomarker: A Systematic Review
■260 ▼a[Sl]▼bYale University▼c2024
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2024
■300 ▼a87 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 85-11, Section: B.
■500 ▼aAdvisor: Escobar-Hoyos, Luisa F.;Shroyer, Kenneth R.
■5021 ▼aThesis (M.D.)--Yale University, 2024.
■520 ▼aBackground: In an era where tumor heterogeneity leads to widely variable cancer treatment outcomes, there is an unmet need for biomarkers that can characterize tumor subtypes, inform prognosis, and guide clinical decision-making for therapy. As an oncofetal monofilament that is only expressed in embryonic and cancer tissue, keratin 17 (K17) has been demonstrated as an effective biomarker in a wide variety of cancer types, detection methods, and clinical purposes. In order to guide and inform future investigations on K17, we performed a systematic review of clinical studies assessing the effectiveness of K17 as a cancer biomarker.Methods: We performed a literature search of relevant articles reporting K17 as a cancer biomarker prior to December 16th, 2023. After manual review, we assigned articles to diagnostic, prognostic, and predictive study categories. We extracted relevant diagnostic and prognostic statistics, experimental methodologies, and co-examined biomarkers. Additionally, we performed bias analysis utilizing data reported from prognostic studies. Finally, using RNA-seq samples of tumor and normal tissue specimens from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) portal, we perform our own diagnostic analysis across 21 tumor/normal tissue pairs, as well as Kaplan-Meier analysis across 32 cancer types.Results: Of the 453 studies identified in our literature search, we obtained 40 diagnostic, 50 prognostic, and 5 predictive studies. Altogether, we summarized the methodologies of 37 diagnostic studies and ROC (Receiver Operating Curve) analyses provided by 15 articles. Our review suggests that K17 is a highly applicable diagnostic biomarker, characterizable by multiple assay types, to distinguish either malignant from normal pathology, or two different malignant pathologies. For prognostic studies, we extracted Cox proportional hazards models provided by 36 studies, a majority of which suggest that K17 is a negatively prognostic biomarker in a wide range of cancer types, including oropharyngeal, esophageal, gastric, pancreatic, gallbladder, ovarian, and endometrial cancers. Finally, based on our review, K17 is predictive of inferior response to therapy in 4 out of 5 predictive studies.Conclusion: K17 is a widely applicable cancer biomarker that has been shown to be effective in diagnostic settings, and increasingly in patient specimens obtained non-invasively. As both an IHC and RNA-based biomarker, K17 is widely associated with negative prognosis. New predictive studies are beginning to correlate K17 to inferior chemotherapeutic and immunotherapeutic treatment response.
■590 ▼aSchool code: 0265.
■650 4▼aMedicine
■650 4▼aMolecular biology
■650 4▼aOncology
■653 ▼aCancer treatment
■653 ▼aTumor heterogeneity
■653 ▼aKeratin 17
■653 ▼aBiomarkers
■690 ▼a0564
■690 ▼a0307
■690 ▼a0992
■71020▼aYale University▼bYale School of Medicine.
■7730 ▼tDissertations Abstracts International▼g85-11B.
■790 ▼a0265
■791 ▼aM.D.
■792 ▼a2024
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17160645▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
